Abstract is: Douglas F. Easton FMedSci is a British epidemiologist who conducts research on the genetics of human cancers. He is Professor of Genetic Epidemiology and Centre for Cancer Genetic Epidemiology at the University of Cambridge. He founded Cambridge's Cancer Research UK Genetic Epidemiology Unit in 1995, and was a Principal Research Fellow there from 2001 to 2011. He is a Professorial Fellow of Homerton College, Cambridge.
| human | Q5 |
| P2671 | Google Knowledge Graph ID | /g/11h2g23drn |
| P1960 | Google Scholar author ID | Iyaf7KUAAAAJ |
| P496 | ORCID iD | 0000-0003-2444-3247 |
| P166 | award received | Fellow of the Royal Society | Q15631401 |
| P27 | country of citizenship | United Kingdom | Q145 |
| P69 | educated at | University of Cambridge | Q35794 |
| University of London | Q170027 | ||
| P108 | employer | University of Cambridge | Q35794 |
| P734 | family name | Easton | Q16869755 |
| Easton | Q16869755 | ||
| Easton | Q16869755 | ||
| P101 | field of work | cancer epidemiology | Q5382717 |
| P735 | given name | Douglas | Q463035 |
| Douglas | Q463035 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P106 | occupation | geneticist | Q3126128 |
| epidemiologist | Q13416803 | ||
| P21 | sex or gender | male | Q6581097 |
| Q36016386 | 11q13 is a susceptibility locus for hormone receptor positive breast cancer |
| Q35871567 | 19p13.1 is a triple-negative-specific breast cancer susceptibility locus |
| Q33848895 | 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy |
| Q35993424 | 4-Hydroxyandrostenedione in the prophylaxis of N-methyl-N-nitrosourea induced mammary tumourigenesis |
| Q36021406 | 7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium |
| Q37169873 | 9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium |
| Q70929979 | A 45-year follow-up of kindred 107 and the search for BRCA2 |
| Q37005064 | A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding |
| Q28384141 | A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer |
| Q35327105 | A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer |
| Q92224274 | A Mendelian randomization analysis of circulating lipid traits and breast cancer risk |
| Q59355837 | A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk |
| Q42676622 | A combined analysis of genome-wide association studies in breast cancer |
| Q34015399 | A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics |
| Q57250674 | A common coding variant in CASP8 is associated with breast cancer risk |
| Q35755874 | A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer |
| Q45181384 | A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability |
| Q35957063 | A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density |
| Q34211808 | A comprehensive examination of breast cancer risk loci in African American women |
| Q34115258 | A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes |
| Q44767511 | A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer |
| Q30816468 | A full-likelihood method for the evaluation of causality of sequence variants from family data |
| Q70462477 | A genetic risk score to guide age-specific, personalized prostate cancer screening |
| Q96683163 | A genetic risk score to personalize prostate cancer screening, applied to population data |
| Q37225298 | A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population |
| Q37272982 | A genome wide linkage search for breast cancer susceptibility genes |
| Q37332232 | A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk |
| Q34613513 | A genome-wide association scan on estrogen receptor-negative breast cancer |
| Q33747778 | A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. |
| Q35747147 | A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23 |
| Q29417084 | A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. |
| Q29417036 | A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. |
| Q33780746 | A genome-wide association study of prognosis in breast cancer |
| Q33855633 | A genome-wide association study of testicular germ cell tumor |
| Q50104901 | A genome-wide association study to identify genetic markers associated with endometrial cancer grade. |
| Q37192589 | A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication |
| Q37568754 | A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease |
| Q28208102 | A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome |
| Q48582050 | A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. |
| Q37619303 | A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium |
| Q55670968 | A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10 |
| Q35089479 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population |
| Q35248192 | A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer |
| Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
| Q36477652 | A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease |
| Q37272989 | A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers |
| Q112727841 | A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q36152991 | A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers |
| Q35699278 | A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma |
| Q55561844 | A novel tumour-based test to identify breast cancer due to BRCA1 and BRCA2 mutations. |
| Q36609757 | A physical analysis of the Y chromosome shows no additional deletions, other than Gr/Gr, associated with testicular germ cell tumour |
| Q33366184 | A pilot study of compositional analysis of the breast and estimation of breast mammographic density using three-dimensional T1-weighted magnetic resonance imaging |
| Q35870483 | A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients |
| Q33680801 | A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland |
| Q37331103 | A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice |
| Q30842685 | A preliminary analysis of consortium data for markers tightly linked to multiple endocrine neoplasia type 2A. |
| Q36612055 | A prospective study of neurofibromatosis type 1 cancer incidence in the UK. |
| Q37081107 | A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer |
| Q91960210 | A response to "Personalised medicine and population health: breast and ovarian cancer" |
| Q37632049 | A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact |
| Q35848518 | A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects |
| Q37599352 | A role for XRCC2 gene polymorphisms in breast cancer risk and survival |
| Q50767379 | A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. |
| Q40368515 | A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers |
| Q33934322 | A survey of homozygous deletions in human cancer genomes |
| Q36492194 | A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes |
| Q74688260 | A systematic review and meta-analysis of family history and risk of ovarian cancer |
| Q33766628 | A systematic review of genetic polymorphisms and breast cancer risk. |
| Q24613870 | A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation |
| Q53008796 | A test of performance of breast MRI interpretation in a multicentre screening study. |
| Q57305942 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer |
| Q44443237 | A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. |
| Q81725988 | A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes |
| Q62583660 | AA9int: SNP interaction pattern search using non-hierarchical additive model set |
| Q34384444 | ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer |
| Q34546389 | ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles |
| Q36626035 | ATM polymorphisms as risk factors for prostate cancer development |
| Q37417780 | AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study |
| Q57903143 | Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22 |
| Q53478895 | Absence of linkage to the ataxia telangiectasia locus in familial breast cancer. |
| Q61970229 | Abstract 2030: The role of genetic variation in calcium-activated potassium channels in breast cancer patients treated with tamoxifen |
| Q61948757 | Abstract 4836: Gene and environment interactions of height and selected candidate SNPs in prostate cancer: results from the PRACTICAL consortium |
| Q115028536 | Abstract 5314: DNA methylation quantitative trait loci and breast cancer risk: Data from nearly 230,000 women of European descent |
| Q61948762 | Abstract LB-448: Genome-wide association study identifies new prostate cancer susceptibility loci |
| Q43613838 | Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom |
| Q67558787 | Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years |
| Q68949333 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer |
| Q24535695 | After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer |
| Q53238843 | Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. |
| Q39437211 | Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers |
| Q91618412 | Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium |
| Q37417691 | Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study |
| Q30779634 | Alcohol consumption and survival after a breast cancer diagnosis: a literature-based meta-analysis and collaborative analysis of data for 29,239 cases |
| Q57266956 | Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome |
| Q46586463 | Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer |
| Q73151213 | Allelotype of uterine leiomyomas |
| Q53246312 | Alzheimer disease is not associated with polymorphisms in the angiotensinogen and renin genes. |
| Q69674842 | An analysis of prognostic factors in early stage Hodgkin's disease |
| Q35194828 | An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. |
| Q57278931 | An autosome-wide scan for linkage disequilibrium-based association in sporadic breast cancer cases in eastern Finland: three candidate regions found |
| Q36073563 | An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression |
| Q34623703 | An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) |
| Q43039351 | An investigation of ACE as a risk factor for dementia and cognitive decline in the general population. |
| Q35618307 | An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers |
| Q74352067 | Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders |
| Q34308746 | Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families |
| Q59591026 | Analysis of alpha-1 antichymotrypsin, presenilin-1, angiotensin-converting enzyme, and methylenetetrahydrofolate reductase loci as candidates for dementia |
| Q57436491 | Analysis of single-nucleotide polymorphisms in the interleukin-4 receptor gene for association with inflammatory bowel disease |
| Q35030350 | Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors |
| Q50961769 | Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity. |
| Q35882873 | Analysis of the contribution of HLA genes to genetic predisposition in inflammatory bowel disease |
| Q35235374 | Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue |
| Q57694707 | Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival |
| Q35681656 | Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis |
| Q47776757 | Apo E and Apo CI loci are associated with dementia in younger but not older late-onset cases |
| Q53229371 | Apo E genotypes and risk of dementia in Down syndrome. |
| Q53228610 | Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. |
| Q35440542 | Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population |
| Q36649112 | Apoptosis, ageing and cancer susceptibility. |
| Q73704841 | Apparent human BRCA1 knockout caused by mispriming during polymerase chain reaction: implications for genetic testing |
| Q68085678 | Application of linked DNA markers to screening families with multiple endocrine neoplasia type 2A |
| Q69910465 | Application of minisatellite DNA probes to linkage in MEN-2 |
| Q34374548 | Area and volumetric density estimation in processed full-field digital mammograms for risk assessment of breast cancer |
| Q35242849 | Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers |
| Q34613673 | Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study |
| Q37118791 | Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels |
| Q33627147 | Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study |
| Q90666760 | Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium |
| Q97070156 | Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers |
| Q35218520 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy |
| Q37684409 | Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer |
| Q64056497 | Association analyses identify 31 new risk loci for colorectal cancer susceptibility |
| Q57305944 | Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci |
| Q45979098 | Association analysis identifies 65 new breast cancer risk loci. |
| Q37623732 | Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease |
| Q36123803 | Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses |
| Q27851709 | Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer |
| Q34087586 | Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data |
| Q33828680 | Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival |
| Q33471495 | Association between common germline genetic variation in 94 candidate genes or regions and risks of invasive epithelial ovarian cancer |
| Q33279162 | Association between common variation in 120 candidate genes and breast cancer risk |
| Q37200998 | Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study |
| Q57694642 | Association between leptin receptor gene polymorphisms and early-onset prostate cancer |
| Q44259268 | Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer |
| Q37292963 | Association of ESR1 gene tagging SNPs with breast cancer risk |
| Q91271723 | Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness |
| Q36072765 | Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study |
| Q46707380 | Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis |
| Q36178189 | Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. |
| Q37684672 | Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. |
| Q37586697 | Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis |
| Q37268494 | Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry |
| Q114182713 | Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment |
| Q99609984 | Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer |
| Q36593602 | Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population |
| Q46121002 | Association of tamoxifen use and reduced risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
| Q57306187 | Association of the Progesterone Receptor Gene with Breast Cancer Risk: A Single-Nucleotide Polymorphism Tagging Approach |
| Q34801008 | Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q35957703 | Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer |
| Q24646663 | Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants |
| Q35934138 | Association studies for finding cancer-susceptibility genetic variants |
| Q37151879 | Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer |
| Q57202712 | Associations among Mammographic Density, Circulating Sex Hormones, and Polymorphisms in Sex Hormone Metabolism Genes in Postmenopausal Women |
| Q119213340 | Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival |
| Q35022847 | Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies |
| Q35523236 | Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q57056093 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis |
| Q36792641 | Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation |
| Q63966080 | Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci |
| Q64118820 | Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci |
| Q61124964 | Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia |
| Q60917552 | Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility |
| Q60907509 | Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry |
| Q60912720 | Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma |
| Q98164569 | Author Correction: The evolutionary history of lethal metastatic prostate cancer |
| Q92904333 | Authors' response: Associations of obesity and circulating insulin and glucose with breast cancer risk |
| Q44953939 | Average age-specific cumulative risk of breast cancer according to type and site of germline mutations in BRCA1 and BRCA2 estimated from multiple-case breast cancer families attending Australian family cancer clinics |
| Q24531993 | Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies |
| Q37507410 | BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface |
| Q91045517 | BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors |
| Q60933652 | BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2 |
| Q57266722 | BRCA1 and BRCA2 Cancer Risks |
| Q64039257 | BRCA1 and BRCA2 Pathogenic Sequence Variants in Women of African Origin or Ancestry |
| Q34480647 | BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families |
| Q24803673 | BRCA1 and BRCA2 mutations in a population-based study of male breast cancer |
| Q46944617 | BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial. |
| Q57694517 | BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial |
| Q38914005 | BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer |
| Q37002955 | BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers |
| Q57306056 | BRCA2 arg372hispolymorphism and epithelial ovarian cancer risk |
| Q35527158 | BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients |
| Q35749421 | Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival |
| Q37045556 | Blood lipids and prostate cancer: a Mendelian randomization analysis |
| Q46115524 | Body mass index and breast cancer survival: a Mendelian randomization analysis |
| Q67839928 | Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years' follow-up |
| Q100457582 | Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk |
| Q114182645 | Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores |
| Q35643852 | Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. |
| Q44602623 | Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations |
| Q43073201 | Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q102073773 | Breast cancer risk factors and their effects on survival: a Mendelian randomisation study |
| Q35940158 | Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. |
| Q44937823 | Breast cancer risks for BRCA1/2 carriers |
| Q43128186 | Breast cancer screening: time to target women at risk |
| Q35562912 | Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study |
| Q34158093 | Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression |
| Q57305977 | Breast-Cancer Risk in Families With Mutations in PALB2 |
| Q34148873 | Breast-cancer risk in families with mutations in PALB2 |
| Q36623059 | CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers |
| Q47236534 | CHEK2 variant I157T may be associated with increased breast cancer risk |
| Q36449203 | CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer |
| Q33994241 | CHEK2, MGMT, SULT1E1 and SULT1A1 polymorphisms and endometrial cancer risk |
| Q36998293 | COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration |
| Q73088381 | CYP17 promoter polymorphism and breast cancer in Australian women under age forty years |
| Q36419325 | CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer |
| Q104495057 | CanRisk Tool - A web interface for the prediction of breast and ovarian cancer risk and the likelihood of carrying genetic pathogenic variants |
| Q34527264 | Cancer Incidence in BRCA1 mutation carriers |
| Q92005489 | Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families |
| Q114657791 | Cancer Risks Associated With and Pathogenic Variants |
| Q33368870 | Cancer incidence in relatives of British Fanconi Anaemia patients |
| Q47648609 | Cancer mortality in relatives of women with breast cancer: the OPCS Study. Office of Population Censuses and Surveys |
| Q47648595 | Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys |
| Q35994447 | Cancer mortality in the first degree relatives of young breast cancer patients |
| Q34422846 | Cancer risks and mortality in heterozygous ATM mutation carriers |
| Q44946113 | Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. |
| Q40580171 | Cancer risks in A-T heterozygotes |
| Q35248795 | Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. |
| Q38787237 | Cancer treatment trials--past failures, current progress and future prospects. |
| Q33577275 | Cancers of the respiratory tract in mustard gas workers |
| Q92636519 | Candidate Causal Variants at the 8p12 Breast Cancer Risk Locus Regulate DUSP4 |
| Q34963894 | Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q28385765 | Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk |
| Q69118450 | Changing distribution of adenocarcinoma of the stomach |
| Q112645829 | Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses |
| Q96962174 | Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q92475989 | Chromatin interactome mapping at 139 independent breast cancer risk signals |
| Q36599631 | Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG |
| Q35782435 | Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer |
| Q57250578 | ClinGen and Genetic Testing |
| Q36787957 | Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort |
| Q52649838 | Clinical presentation as a predictor of laparotomy findings in supradiaphragmatic stage I and II Hodgkin's disease. |
| Q34227099 | Clinical software development for the Web: lessons learned from the BOADICEA project |
| Q52672618 | Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. |
| Q94486442 | Combined associations of a polygenic risk score and classical risk factors with breast cancer risk |
| Q33627208 | Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients |
| Q37368000 | Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms |
| Q91013280 | Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. |
| Q73139263 | Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population |
| Q24797594 | Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study |
| Q35668946 | Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk |
| Q36490507 | Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). |
| Q57265809 | Common Polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not Associated with Breast Cancer Risk |
| Q57306188 | Common Variants in RB1 Gene and Risk of Invasive Ovarian Cancer |
| Q36839777 | Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34394665 | Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction |
| Q35889575 | Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q35891162 | Common breast cancer susceptibility loci are associated with triple-negative breast cancer |
| Q36600605 | Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk |
| Q24655824 | Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q36856357 | Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls |
| Q33742096 | Common genetic variants and modification of penetrance of BRCA2-associated breast cancer |
| Q35817086 | Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis |
| Q34949394 | Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers |
| Q24658131 | Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer |
| Q34651737 | Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer |
| Q35794653 | Common germline polymorphisms associated with breast cancer-specific survival |
| Q45263043 | Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer |
| Q59654812 | Common germline variation in mismatch repair genes and survival after a diagnosis of colorectal cancer |
| Q34379032 | Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium |
| Q73806219 | Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk |
| Q28237788 | Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival |
| Q46209474 | Common single-nucleotide polymorphisms in DNA double-strand break repair genes and breast cancer risk |
| Q98390794 | Common susceptibility loci for male breast cancer |
| Q33947829 | Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q36393232 | Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers |
| Q29417145 | Common variants at 19p13 are associated with susceptibility to ovarian cancer |
| Q35870067 | Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q36255665 | Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer |
| Q37434133 | Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q34792833 | Common variants in ZNF365 are associated with both mammographic density and breast cancer risk |
| Q115209587 | Common variants in breast cancer risk loci predispose to distinct tumor subtypes |
| Q57306185 | Common variants in mismatch repair genes and risk of colorectal cancer |
| Q53345077 | Common variants in mismatch repair genes and risk of invasive ovarian cancer. |
| Q35794359 | Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk |
| Q34213403 | Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers |
| Q21260438 | Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs |
| Q57306038 | Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness |
| Q29417133 | Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q68624359 | Comparison of conservative surgery and radiotherapy with mastectomy in the treatment of early breast cancer |
| Q37121925 | Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics |
| Q104493300 | Comprehensive Functional Characterization and Clinical Interpretation of 20 Splice-Site Variants of the RAD51C Gene |
| Q37533894 | Comprehensive functional annotation of 77 prostate cancer risk loci |
| Q36026731 | Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q53464409 | Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. |
| Q37155532 | Consortium analysis of 7 candidate SNPs for ovarian cancer |
| Q57694758 | Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings |
| Q81736126 | Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France |
| Q73215230 | Contribution of BRCA1 mutations to ovarian cancer |
| Q78852982 | Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma |
| Q92097678 | Correction to: Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey |
| Q93118070 | Correction to: Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer |
| Q89897900 | Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers |
| Q91763335 | Correction: BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors |
| Q57266620 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer |
| Q45793899 | Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q46958735 | Correction: Evaluating Genome-Wide Association Study-Identified Breast Cancer Risk Variants in African-American Women. |
| Q50086096 | Corrections to: Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries. |
| Q57565042 | Corrigendum re “Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma” [Eur Urol 2017;72:747–54] |
| Q50092775 | Corrigendum: A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers. |
| Q43102129 | Corrigendum: Rare coding variants and X-linked loci associated with age at menarche |
| Q36611741 | Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer |
| Q30444093 | Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model |
| Q37533025 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer |
| Q28396029 | Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer |
| Q28388475 | Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations |
| Q30660858 | Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer |
| Q92184158 | Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer |
| Q21144874 | DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q37685729 | DNA mismatch repair gene MSH6 implicated in determining age at natural menopause |
| Q44212883 | Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues |
| Q100455702 | Detecting rare copy number variants from Illumina genotyping arrays with the CamCNV pipeline: Segmentation of z-scores improves detection and reliability |
| Q36696498 | Diagnostic radiation procedures and risk of prostate cancer |
| Q43457233 | Dietary fat and early-onset prostate cancer risk |
| Q58546894 | Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer |
| Q60472142 | Discovery of common and rare genetic risk variants for colorectal cancer |
| Q27851413 | Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium |
| Q55110745 | E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. |
| Q48769845 | Educational attainment and mean leukocyte telomere length in women in the European Prospective Investigation into Cancer (EPIC)-Norfolk population study. |
| Q52838313 | Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. |
| Q51798328 | Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. |
| Q64387842 | Effect of germ-line genetic variation on breast cancer survival in a population-based study |
| Q36245609 | Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers |
| Q36724762 | Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival |
| Q36787362 | Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort |
| Q57694442 | Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers |
| Q33847327 | Eligibility for magnetic resonance imaging screening in the United Kingdom: effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS Study |
| Q34778269 | Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study |
| Q104466347 | Epidemiological and ES cell-based Functional Evaluation of BRCA2 Variants Identified in Families with Breast Cancer |
| Q24633316 | Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer |
| Q36487146 | Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk |
| Q57250672 | Erratum: Corrigendum: A common coding variant in CASP8 is associated with breast cancer risk |
| Q57694301 | Erratum: Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue |
| Q57319395 | Erratum: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer |
| Q57202568 | Erratum: Corrigendum: Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk |
| Q59041387 | Erratum: Identification of the breast cancer susceptibility gene BRCA2 |
| Q35644167 | Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence |
| Q51766497 | Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. |
| Q98184153 | European polygenic risk score for prediction of breast cancer shows similar performance in Asian women |
| Q90109747 | Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study |
| Q36388749 | Evaluating genetic risk for prostate cancer among Japanese and Latinos |
| Q40238343 | Evaluating genetic variants associated with breast cancer risk in high and moderate-penetrance genes in Asians |
| Q34339783 | Evaluating genome-wide association study-identified breast cancer risk variants in African-American women |
| Q46397060 | Evaluating the effectiveness of using standard mammogram form to predict breast cancer risk: case-control study |
| Q84488690 | Evaluating the power to discriminate between highly correlated SNPs in genetic association studies |
| Q99720321 | Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses |
| Q37004792 | Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer |
| Q57266770 | Evaluation of Fanconi Anemia genes in familial breast cancer predisposition |
| Q33614244 | Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers |
| Q37481884 | Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). |
| Q53537306 | Evaluation of a prospective scoring system designed for a multicenter breast MR imaging screening study. |
| Q51955474 | Evaluation of an algorithm of tagging SNPs selection by linkage disequilibrium. |
| Q52887813 | Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. |
| Q33595844 | Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies |
| Q91549968 | Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk |
| Q36352389 | Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers |
| Q33894527 | Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium |
| Q34806825 | Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. |
| Q35653910 | Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk |
| Q34613604 | Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers |
| Q74157664 | Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study |
| Q36067788 | Evidence of a Causal Association Between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis |
| Q36720821 | Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors |
| Q33680361 | Evidence of linkage of the inflammatory bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis |
| Q35064451 | Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation |
| Q37342144 | Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation |
| Q69900961 | Exclusion of linkage of loci on chromosome 19 with multiple endocrine neoplasia, type 2 |
| Q40039502 | Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients |
| Q47726410 | Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer |
| Q33863235 | Exploring the link between MORF4L1 and risk of breast cancer |
| Q34298114 | Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). |
| Q37594336 | FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium |
| Q37323340 | FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation |
| Q57591362 | Familial cancer syndromes |
| Q28284637 | Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13: evidence for its role as a tumour suppressor gene |
| Q73670879 | Familial predisposition to breast cancer in a British population: implications for prevention |
| Q41409355 | Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study |
| Q33892928 | Familial relative risks for breast cancer by pathological subtype: a population-based cohort study |
| Q24802759 | Familial risks of breast cancer |
| Q35889576 | Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. |
| Q41495151 | Family history and the risk of breast cancer: a systematic review and meta-analysis |
| Q43002090 | Family history of breast cancer: referral guidelines changed after acceptance of 10 minute consultation |
| Q31056324 | FastPop: a rapid principal component derived method to infer intercontinental ancestry using genetic data |
| Q37236216 | Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). |
| Q33878276 | Fine scale mapping of the breast cancer 16q12 locus |
| Q36111237 | Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus |
| Q36087170 | Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q36856343 | Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression |
| Q55380382 | Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. |
| Q35524465 | Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. |
| Q61230414 | Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes |
| Q92480972 | Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes |
| Q55311842 | Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. |
| Q35063160 | Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk |
| Q35097143 | Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer |
| Q39844032 | Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer |
| Q36248936 | Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk |
| Q34903062 | Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. |
| Q37367871 | Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. |
| Q37002930 | Five endometrial cancer risk loci identified through genome-wide association analysis |
| Q34979715 | Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium |
| Q44693258 | Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group |
| Q44886773 | Frequency of familial melanoma and MLM2 gene. |
| Q46943059 | From association to cause: fine mapping of the TNRC9 gene region, a novel susceptibility locus identified in the first genome-wide association study for breast cancer. |
| Q114182808 | Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element |
| Q34958831 | Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival |
| Q59197822 | Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival |
| Q36124728 | Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus |
| Q34031757 | Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers |
| Q36742577 | Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers |
| Q36956156 | GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer |
| Q38408978 | GWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer |
| Q35952814 | Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array |
| Q50041886 | Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. |
| Q40137431 | Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium |
| Q34017597 | Gene-gene interactions in breast cancer susceptibility |
| Q36175072 | Gene-panel sequencing and the prediction of breast-cancer risk |
| Q34716723 | Generalizability of established prostate cancer risk variants in men of African ancestry |
| Q37389405 | Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer |
| Q39200248 | Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma |
| Q115209620 | Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus |
| Q57306006 | Genetic and Histopathologic Evaluation ofBRCA1andBRCA2DNA Sequence Variants of Unknown Clinical Significance |
| Q35437187 | Genetic association of an LBP-1c/CP2/LSF gene polymorphism with late onset Alzheimer's disease |
| Q33379396 | Genetic evidence and integration of various data sources for classifying uncertain variants into a single model |
| Q35194190 | Genetic heterogeneity and localization of a familial breast-ovarian cancer gene on chromosome 17q12-q21 |
| Q29619206 | Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium |
| Q42950856 | Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium |
| Q108609948 | Genetic insights into biological mechanisms governing human ovarian ageing |
| Q24671905 | Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium |
| Q60672873 | Genetic linkage studies map the multiple endocrine neoplasia type 2 loci to a small interval on chromosome 10q11.2 |
| Q48605185 | Genetic models for the familial aggregation of mammographic breast density. |
| Q37739048 | Genetic modifiers of CHEK2*1100delC-associated breast cancer risk |
| Q29417068 | Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study |
| Q54940815 | Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. |
| Q35925620 | Genetic predisposition to ductal carcinoma in situ of the breast |
| Q35151684 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast |
| Q91362827 | Genetic predisposition to mosaic Y chromosome loss in blood |
| Q61229415 | Genetic predisposition to mosaic Y chromosome loss in blood is associated with genomic instability in other tissues and susceptibility to non-haematological cancers |
| Q41130542 | Genetic susceptibility to breast cancer |
| Q35994225 | Genetic susceptibility to naevi – a twin study |
| Q62583135 | Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma |
| Q63976721 | Genetic variant predictors of gene expression provide new insight into risk of colorectal cancer |
| Q43415543 | Genetic variants associated with predisposition to prostate cancer and potential clinical implications |
| Q28481918 | Genetic variants in ER cofactor genes and endometrial cancer risk |
| Q34497690 | Genetic variants in epigenetic genes and breast cancer risk. |
| Q35022825 | Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers |
| Q35179897 | Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study |
| Q34453723 | Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium |
| Q34378972 | Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade |
| Q28943405 | Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies |
| Q37131328 | Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies |
| Q37311599 | Genetic variation in the chromosome 17q23 amplicon and breast cancer risk |
| Q36422109 | Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium |
| Q30000080 | Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent |
| Q92387949 | Genetically Predicted Levels of DNA Methylation Biomarkers and Breast Cancer Risk: Data From 228 951 Women of European Descent |
| Q28388497 | Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q63681757 | Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer |
| Q93270780 | Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q53316917 | Genome-wide association studies in cancer. |
| Q37736894 | Genome-wide association studies in common cancers--what have we learnt? |
| Q37202841 | Genome-wide association study for ovarian cancer susceptibility using pooled DNA. |
| Q29417100 | Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer |
| Q95329367 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses |
| Q29417135 | Genome-wide association study identifies a common variant associated with risk of endometrial cancer |
| Q29417050 | Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk |
| Q36024614 | Genome-wide association study identifies a possible susceptibility locus for endometrial cancer |
| Q34114293 | Genome-wide association study identifies five new breast cancer susceptibility loci |
| Q35061252 | Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk |
| Q33804470 | Genome-wide association study identifies multiple risk loci for renal cell carcinoma |
| Q28924380 | Genome-wide association study identifies new prostate cancer susceptibility loci |
| Q24645441 | Genome-wide association study identifies novel breast cancer susceptibility loci |
| Q52720511 | Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. |
| Q29416994 | Genome-wide association study identifies three new melanoma susceptibility loci |
| Q59795648 | Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma |
| Q27008356 | Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk |
| Q34295620 | Genome-wide association study of circulating estradiol, testosterone, and sex hormone-binding globulin in postmenopausal women |
| Q47125417 | Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility |
| Q28660394 | Genome-wide association study of endometrial cancer in E2C2 |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q38970751 | Genome-wide association study of prostate cancer-specific survival |
| Q28943264 | Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3 |
| Q33778612 | Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. |
| Q35615396 | Genome-wide association study of susceptibility loci for breast cancer in Sardinian population |
| Q36190531 | Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses |
| Q53349500 | Genome-wide linkage disequilibrium mapping of late-onset Alzheimer's disease in Finland. |
| Q44816258 | Genome-wide linkage screen for testicular germ cell tumour susceptibility loci |
| Q36019187 | Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma |
| Q59566871 | Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility |
| Q38823212 | Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk |
| Q90633174 | Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan |
| Q47552886 | Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study |
| Q27852185 | Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer |
| Q35949522 | Germline BRCA1 mutations increase prostate cancer risk |
| Q96432094 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk |
| Q58050324 | Germline determinants of the somatic mutation landscape in 2,642 cancer genomes |
| Q35114576 | Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer |
| Q48006281 | Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer |
| Q57266937 | Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype–phenotype correlation |
| Q114182677 | Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis |
| Q58611475 | Germline variation at 8q24 and prostate cancer risk in men of European ancestry |
| Q71219856 | HLA and inflammatory bowel disease |
| Q36503369 | HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). |
| Q36646188 | HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease |
| Q34577582 | Hand pattern indicates prostate cancer risk |
| Q36612585 | HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer |
| Q34385784 | Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study |
| Q35881432 | Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study |
| Q35382206 | Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers |
| Q57471595 | Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study |
| Q36276540 | Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization |
| Q38647896 | Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium |
| Q62583666 | Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium |
| Q33330850 | Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics |
| Q36547888 | Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers |
| Q57419184 | High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients |
| Q57694680 | High risk genes predisposing to prostate cancer development—do they exist? |
| Q119213179 | High-throughput allelic expression imbalance analyses identify candidate breast cancer risk genes |
| Q37121271 | High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium |
| Q24800566 | How many more breast cancer predisposition genes are there? |
| Q41483086 | Human familial and sporadic breast cancer: analysis of the coding regions of the 17 beta-hydroxysteroid dehydrogenase 2 gene (EDH17B2) using a single-strand conformation polymorphism assay |
| Q28303249 | Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer |
| Q57202722 | IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q37006170 | Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. |
| Q30252854 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer |
| Q39182862 | Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor |
| Q29417155 | Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array |
| Q100512295 | Identification of 31 loci for mammographic density phenotypes and their associations with breast cancer risk |
| Q99210133 | Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening |
| Q36720814 | Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk |
| Q36062033 | Identification of a novel percent mammographic density locus at 12q24. |
| Q34975918 | Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript |
| Q24653491 | Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women |
| Q36839486 | Identification of four new susceptibility loci for testicular germ cell tumour |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q58743933 | Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma |
| Q37074763 | Identification of new genetic risk factors for prostate cancer |
| Q34038964 | Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions |
| Q57170142 | Identification of nine new susceptibility loci for endometrial cancer |
| Q36922317 | Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14 |
| Q90091185 | Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants |
| Q36014067 | Identification of novel genetic markers of breast cancer survival |
| Q29417022 | Identification of seven new prostate cancer susceptibility loci through a genome-wide association study |
| Q36331604 | Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions |
| Q35541663 | Identification of six new susceptibility loci for invasive epithelial ovarian cancer |
| Q46103372 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer |
| Q43799475 | Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis |
| Q35602297 | Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis |
| Q36799777 | Incorporating Functional Genomic Information in Genetic Association Studies Using an Empirical Bayes Approach |
| Q114184688 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model |
| Q37378034 | Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model |
| Q34048046 | Incorporating tumour pathology information into breast cancer risk prediction algorithms |
| Q57694657 | Influence of cytokine gene polymorphisms on the development of prostate cancer |
| Q37410472 | Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women |
| Q38131236 | Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning? |
| Q47586106 | Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia |
| Q40662115 | Inherited susceptibility to breast cancer |
| Q35104068 | Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer |
| Q28261987 | Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease |
| Q33910123 | Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2 |
| Q36065460 | Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions |
| Q24652651 | Interactions between genes involved in the antioxidant defence system and breast cancer risk |
| Q28277066 | Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial |
| Q24611474 | International network of cancer genome projects |
| Q34081324 | Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer |
| Q40515571 | Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis |
| Q34898735 | Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors |
| Q60182876 | Is Schizophrenia a Risk Factor for Breast Cancer?—Evidence From Genetic Data |
| Q57269243 | Is the genetics of moliness simply the genetics of sun exposure? A path analysis of nevus counts and risk factors in British twins |
| Q64279327 | Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk |
| Q47190168 | Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium |
| Q57191573 | Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair |
| Q62583667 | Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology |
| Q28267893 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q53509871 | Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. |
| Q89635615 | Letter to the editor: a response to Ming's study on machine learning techniques for personalized breast cancer risk prediction |
| Q50793046 | Life stress, emotional health, and mean telomere length in the European Prospective Investigation into Cancer (EPIC)-Norfolk population study. |
| Q34546040 | Lifetime risks of common cancers among retinoblastoma survivors |
| Q41249785 | Linkage analysis and genetic models for IDDM. |
| Q69444426 | Linkage analysis in non-Mendelian disorders |
| Q43076324 | Linkage analysis of 56 multiplex families excludes the Cowden disease gene PTEN as a major contributor to familial breast cancer. |
| Q33675797 | Linkage analysis of British and Indian families with Von Recklinghausen neurofibromatosis |
| Q35247343 | Linkage analysis of chromosome 17 markers in British and South African families with neurofibromatosis type I. |
| Q24538779 | Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators |
| Q59070031 | Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA regions |
| Q43742561 | Linked markers flanking the gene for multiple endocrine neoplasia type 2A. |
| Q47906696 | Localisation of susceptibility genes for familial testicular germ cell tumour |
| Q57250791 | Localisation of the breast-ovarian cancer susceptibility gene (BRCAI) on 17q12–21 to an interval of IcM |
| Q57694734 | Localization of the gene for Cowden disease to chromosome 10q22–23 |
| Q33888459 | Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours |
| Q35119701 | Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium |
| Q46361479 | Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study (IBCCS). |
| Q28215462 | Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations |
| Q34700093 | Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status |
| Q24597674 | Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours |
| Q58177980 | MEDULLOBLASTOMA |
| Q44439883 | Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer |
| Q50665913 | Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. |
| Q31043651 | Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. |
| Q36043843 | Mammographic breast density and breast cancer: evidence of a shared genetic basis |
| Q51820769 | Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. |
| Q84086394 | Mammographic density, estrogen receptor status and other breast cancer tumor characteristics |
| Q70196146 | Measurement of 1,25-dihydroxyvitamin D3 receptors in breast cancer and their relationship to biochemical and clinical indices |
| Q92860654 | Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers |
| Q114182490 | Mendelian randomisation study of smoking exposure in relation to breast cancer risk |
| Q98772941 | Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer |
| Q93370418 | Mendelian randomization analysis of C-reactive protein on colorectal cancer risk |
| Q30276350 | Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. |
| Q36333368 | Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. |
| Q63352621 | Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q34072919 | Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases |
| Q41705634 | Mismatch repair gene polymorphisms and survival in invasive ovarian cancer patients |
| Q34123806 | Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls |
| Q38519765 | Models for respiratory cancer in nickel refinery workers |
| Q35982332 | Models for skin tumour risks in workers exposed to mineral oils |
| Q36602581 | Models of genetic susceptibility to breast cancer |
| Q35207476 | Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes |
| Q53688849 | More on Co-Occurrence of COMT and BRCA1/2 Variants in a Population. |
| Q33583512 | Mortality from respiratory cancer and other causes in United Kingdom chromate production workers |
| Q34736858 | Most common 'sporadic' cancers have a significant germline genetic component |
| Q35221378 | Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25 |
| Q47696751 | Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations |
| Q36897003 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer |
| Q50582715 | Multiple loci on 8q24 associated with prostate cancer susceptibility. |
| Q33988405 | Multiple loci with different cancer specificities within the 8q24 gene desert |
| Q28268180 | Multiple newly identified loci associated with prostate cancer susceptibility |
| Q30491647 | Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium |
| Q35646703 | Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans |
| Q33630836 | Mutation analysis of the MSMB gene in familial prostate cancer |
| Q49024646 | Mutational Spectrum in a Worldwide Study of 29,700 Families with BRCA1 or BRCA2 Mutations. |
| Q28284058 | Mutations in CUL4B, which encodes a ubiquitin E3 ligase subunit, cause an X-linked mental retardation syndrome associated with aggressive outbursts, seizures, relative macrocephaly, central obesity, hypogonadism, pes cavus, and tremor |
| Q24682652 | Mutations in ZDHHC9, which encodes a palmitoyltransferase of NRAS and HRAS, cause X-linked mental retardation associated with a Marfanoid habitus |
| Q33998564 | Mutations in the DLG3 gene cause nonsyndromic X-linked mental retardation |
| Q24671723 | Mutations in the gene encoding the Sigma 2 subunit of the adaptor protein 1 complex, AP1S2, cause X-linked mental retardation |
| Q34988026 | National Cancer Institute Prostate Cancer Genetics Workshop |
| Q26799669 | Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk |
| Q37356243 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. |
| Q34057961 | No association between FTO or HHEX and endometrial cancer risk |
| Q33982873 | No association between TERT-CLPTM1L single nucleotide polymorphism rs401681 and mean telomere length or cancer risk |
| Q36292769 | No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer |
| Q53417363 | No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. |
| Q37237352 | No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study |
| Q30374367 | No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. |
| Q28211288 | No evidence for an association between Saitohin Q7R polymorphism and Alzheimer's disease |
| Q43956251 | No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families |
| Q43076118 | No evidence of germline PTEN mutations in familial prostate cancer |
| Q51699099 | No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. |
| Q37308596 | No evidence that GATA3 rs570613 SNP modifies breast cancer risk |
| Q37079859 | No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing |
| Q41931445 | No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group |
| Q92476025 | Non-coding RNAs underlie genetic predisposition to breast cancer |
| Q35752042 | Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures |
| Q56359054 | Novel Common Genetic Susceptibility Loci for Colorectal Cancer |
| Q35528419 | Novel bayes factors that capture expert uncertainty in prior density specification in genetic association studies |
| Q35238500 | Optimal strategies for mapping complex diseases in the presence of multiple loci |
| Q92281866 | Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study |
| Q94355841 | Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS) |
| Q34652262 | Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group |
| Q89927576 | Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D |
| Q56438023 | Ovarian and breast cancer risks to women in families with two or more cases of ovarian cancer |
| Q44058392 | Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants |
| Q59548827 | Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus |
| Q36280191 | Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers |
| Q28267299 | Overexpression of RAD51 occurs in aggressive prostatic cancer |
| Q28584533 | PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS |
| Q24615080 | PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene |
| Q47143943 | PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1. |
| Q57315735 | PROTEIN-CODING VARIANTS IMPLICATE NOVEL GENES RELATED TO LIPID HOMEOSTASIS CONTRIBUTING TO BODY FAT DISTRIBUTION |
| Q34289136 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche |
| Q35633640 | Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers |
| Q36417799 | Partnering in oncogenetic research--the INHERIT BRCAs experience: opportunities and challenges |
| Q112572520 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes |
| Q35737888 | Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) |
| Q35741630 | Pathology of ovarian cancers in BRCA1 and BRCA2 carriers |
| Q37307937 | Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium |
| Q29547841 | Patterns of somatic mutation in human cancer genomes |
| Q36873786 | Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium |
| Q96577047 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
| Q98775279 | Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History |
| Q45164991 | Physical activity and mammographic breast density in the EPIC-Norfolk cohort study |
| Q81523323 | Polygenes, risk prediction, and targeted prevention of breast cancer |
| Q57306194 | Polygenic Inherited Predisposition to Breast Cancer |
| Q62583133 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes |
| Q47561710 | Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts |
| Q79162761 | Polygenic inheritance of breast cancer: Implications for design of association studies |
| Q37131918 | Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families |
| Q97524107 | Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants |
| Q78029012 | Polygenic susceptibility to breast cancer and implications for prevention |
| Q34977428 | Polygenic susceptibility to prostate and breast cancer: implications for personalised screening |
| Q57499707 | Polyglutamine repeat length in theAIB1 gene modifies breast cancer susceptibility inBRCA1 carriers |
| Q24648412 | Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women |
| Q44938215 | Polymorphisms associated with circulating sex hormone levels in postmenopausal women |
| Q43792195 | Polymorphisms in CYP1A1 and smoking: no association with breast cancer risk |
| Q57306195 | Polymorphisms in DNA repair genes and epithelial ovarian cancer risk |
| Q36066735 | Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression |
| Q36915870 | Polymorphisms in inflammation pathway genes and endometrial cancer risk |
| Q53414081 | Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. |
| Q34434293 | Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis. |
| Q39524941 | Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium |
| Q34780052 | Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q47590869 | Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics |
| Q73022855 | Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study |
| Q36287185 | Population-based family studies in genetic epidemiology |
| Q31152672 | Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics |
| Q92055460 | Prediction and clinical utility of a contralateral breast cancer risk model |
| Q42481495 | Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype |
| Q36356727 | Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores |
| Q37487782 | Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q91832507 | Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts |
| Q41584352 | Prediction of individual genetic risk to prostate cancer using a polygenic score |
| Q64951428 | Preface to the breast cancer linkage consortium papers. |
| Q36168475 | Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS) |
| Q69007330 | Presurgical determination of estrogen receptor status using immunocytochemically stained fine needle aspirate smears in patients with breast cancer |
| Q44951307 | Presymptomatic screening for multiple endocrine neoplasia type 2A with linked DNA markers. The MEN 2A International Collaborative Group |
| Q77845970 | Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer |
| Q62583372 | Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort |
| Q69012280 | Prognosis following chemotherapy for metastatic malignant teratoma |
| Q70538425 | Prognostic factors in non-infiltrating carcinoma of the bladder: a preliminary report |
| Q68966333 | Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy |
| Q37350137 | Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups |
| Q70929991 | Prophylactic oophorectomy in inherited breast/ovarian cancer families |
| Q96346840 | Prostate Cancer Risk by BRCA2 Genomic Regions |
| Q93179267 | Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study |
| Q34168304 | Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. |
| Q36614710 | Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype |
| Q33640983 | Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status |
| Q57265692 | Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies |
| Q47177885 | Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity |
| Q62839973 | Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution |
| Q50736328 | Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. |
| Q36765569 | Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort |
| Q55508030 | Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. |
| Q96816951 | Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
| Q92503516 | Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity |
| Q51762287 | Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. |
| Q51779676 | Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. |
| Q90242034 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers |
| Q38668303 | Quantifying the Genetic Correlation between Multiple Cancer Types |
| Q36512097 | RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies |
| Q36009422 | RAD51B in Familial Breast Cancer |
| Q57306197 | RESPONSE: Re: Polymorphisms Associated With Circulating Sex Hormone Levels in Postmenopausal Women |
| Q30833608 | Radiogenomics: radiobiology enters the era of big data and team science |
| Q29583867 | Rare and low-frequency coding variants alter human adult height |
| Q35961979 | Rare coding variants and X-linked loci associated with age at menarche |
| Q51102391 | Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition. |
| Q114182625 | Rare germline copy number variants (CNVs) and breast cancer risk |
| Q40094101 | Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks |
| Q35741115 | Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk |
| Q57266855 | Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer |
| Q90821315 | Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry |
| Q74252260 | Re: "Presenting statistical uncertainty in trends and dose-response relations" |
| Q45151860 | Re: On the use of familial aggregation in population-based case probands for calculating penetrance |
| Q52041148 | Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. |
| Q38697838 | Reducing GWAS Complexity |
| Q35155449 | Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia |
| Q68093169 | Regional localization of polymorphic markers on chromosome 10 by physical and genetic mapping |
| Q43659559 | Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer |
| Q68880685 | Repair in the mouse lung during low dose-rate irradiation |
| Q94346063 | Reply: Remarks on the BOADICEA model of genetic susceptibility to breast and ovarian Cancer Research UK |
| Q57694419 | Reply: ‘Hand pattern indicates risk of prostate cancer’ |
| Q44884896 | Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study |
| Q45951126 | Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. |
| Q69566058 | Response of nitrosomethylurea-induced rat mammary tumor to endocrine therapy and comparison with clinical response |
| Q35992084 | Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer |
| Q54309392 | Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium. |
| Q42730960 | Risk Analysis of Prostate Cancer in PRACTICAL Consortium--Response |
| Q35815958 | Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci |
| Q69912692 | Risk estimation and screening in families of patients with medullary thyroid carcinoma |
| Q36497505 | Risk factors and clinical data related to oestrogen receptor status in women presenting with breast cancer |
| Q43428196 | Risk factors for the incidence of breast cancer: do they affect survival from the disease? |
| Q73371929 | Risk models for familial ovarian and breast cancer |
| Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
| Q36430753 | Risk prediction models for familial breast cancer |
| Q92708085 | Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers |
| Q38717239 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers |
| Q52724999 | Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. |
| Q34724404 | Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium |
| Q46776482 | Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers |
| Q36671646 | Role of MC1R variants in uveal melanoma |
| Q91918447 | Runs of homozygosity and testicular cancer risk |
| Q38382935 | SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns |
| Q36545934 | SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival |
| Q37440810 | SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design? |
| Q45091978 | STK15 polymorphisms and association with risk of invasive ovarian cancer. |
| Q44086012 | Sampling distribution of summary linkage disequilibrium measures |
| Q39908314 | Screening for prostate cancer: the way ahead |
| Q57266712 | Screening for theBRCA1-ins6kbEx13mutation: potential for misdiagnosis |
| Q50761882 | Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). |
| Q33467087 | Seq4SNPs: new software for retrieval of multiple, accurately annotated DNA sequences, ready formatted for SNP assay design |
| Q34788325 | Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results |
| Q52584573 | Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. |
| Q29417074 | Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study |
| Q92969786 | Sex specific associations in genome wide association analysis of renal cell carcinoma |
| Q21558581 | Sexual activity and prostate cancer risk in men diagnosed at a younger age |
| Q61118451 | Shared heritability and functional enrichment across six solid cancers |
| Q64004349 | Shared heritability and functional enrichment across six solid cancers |
| Q37151786 | Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer |
| Q36614423 | Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population |
| Q36974533 | Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature |
| Q36697196 | Somatic mutations of KIT in familial testicular germ cell tumours |
| Q40377902 | Somatic mutations of the protein kinase gene family in human lung cancer |
| Q36536620 | Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast |
| Q35038448 | Statistical analysis of pathogenicity of somatic mutations in cancer |
| Q33593016 | Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies |
| Q43076184 | Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36. The CRC/BPG UK Familial Prostate Cancer Study Coordinators and Collaborators. The EU Biomed Collaborators |
| Q74462145 | Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group |
| Q68094580 | Survival of patients with breast cancer attending Bristol Cancer Help Centre |
| Q59548851 | Systematic Population-Based Assessment of Cancer Risk in First-Degree Relatives of Cancer Probands |
| Q35038651 | TGF-β signaling pathway and breast cancer susceptibility |
| Q33566957 | TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer |
| Q50690518 | Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. |
| Q33277172 | Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer |
| Q34486210 | Tagging single-nucleotide polymorphisms in antioxidant defense enzymes and susceptibility to breast cancer |
| Q37141940 | Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer |
| Q37122297 | Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers |
| Q91044035 | Targeted Resequencing of the Coding Sequence of 38 Genes Near Breast Cancer GWAS Loci in a Large Case-Control Study |
| Q46935108 | Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study |
| Q36624435 | Teacher questionnaire compared with observational data on effects of sex and sibling status on preschool behaviour |
| Q33794700 | Telomere length in prospective and retrospective cancer case-control studies |
| Q37529386 | Telomere length shows no association with BRCA1 and BRCA2 mutation status |
| Q28397509 | Telomere structure and maintenance gene variants and risk of five cancer types |
| Q36610793 | Testicular microlithiasis as a familial risk factor for testicular germ cell tumour |
| Q35435738 | The ACE gene and Alzheimer's disease susceptibility |
| Q57250694 | The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers |
| Q32106726 | The BACE gene: genomic structure and candidate gene study in late-onset Alzheimer's disease. |
| Q36695832 | The BOADICEA model of genetic susceptibility to breast and ovarian cancer |
| Q36615665 | The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions |
| Q45973022 | The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. |
| Q49817640 | The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. |
| Q33300099 | The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study |
| Q57436750 | The CEPH consortium primary linkage map of human chromosome 10 |
| Q33675997 | The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q58174815 | The Effects of Common Genetic Variants in Oncogenes on Ovarian Cancer Survival |
| Q91178389 | The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer |
| Q64116004 | The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations |
| Q33937556 | The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred |
| Q34115636 | The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q37578078 | The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers |
| Q68429079 | The Relationship Between Micrometastases in the Bone Marrow, Histopathologic Features of the Primary Tumor in Breast Cancer and Prognosis |
| Q57306198 | The Reliable Identification of Disease-Gene Associations |
| Q35781316 | The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients |
| Q37401496 | The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q57266790 | The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS) |
| Q34137428 | The Y deletion gr/gr and susceptibility to testicular germ cell tumor |
| Q34759322 | The admixture maximum likelihood test to test for association between rare variants and disease phenotypes |
| Q80298785 | The admixture maximum likelihood test: a novel experiment-wise test of association between disease and multiple SNPs |
| Q24797305 | The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers |
| Q35247066 | The clinical and screening age-at-onset distribution for the MEN-2 syndrome |
| Q34145680 | The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes |
| Q37804082 | The contribution of inherited predisposition to cancer incidence |
| Q38856899 | The contribution of rare variation to prostate cancer heritability |
| Q36137764 | The contributions of breast density and common genetic variation to breast cancer risk |
| Q57266710 | The cost-utility of magnetic resonance imaging for breast cancer in BRCA1 mutation carriers aged 30–49 |
| Q96230855 | The effect of sample size on polygenic hazard models for prostate cancer |
| Q36133295 | The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium |
| Q35548366 | The evolutionary history of lethal metastatic prostate cancer |
| Q34144358 | The extent of linkage disequilibrium in four populations with distinct demographic histories |
| Q57694684 | The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators |
| Q64998464 | The functional ALDH2 polymorphism is associated with breast cancer risk: A pooled analysis from the Breast Cancer Association Consortium. |
| Q72690831 | The genetic epidemiology of BRCA1. Breast Cancer Linkage Consortium |
| Q35959353 | The genetic epidemiology of breast cancer genes |
| Q34146408 | The genetic epidemiology of early-onset epithelial ovarian cancer: a population-based study |
| Q38168060 | The genetic epidemiology of prostate cancer and its clinical implications |
| Q93054131 | The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis |
| Q36081587 | The genetics of breast and ovarian cancer |
| Q40654461 | The genetics of familial breast cancer and their practical implications |
| Q42673208 | The heritability of mammographic breast density and circulating sex-hormone levels: two independent breast cancer risk factors |
| Q60921979 | The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study |
| Q40648157 | The inherited component of cancer |
| Q29614637 | The landscape of cancer genes and mutational processes in breast cancer |
| Q69035590 | The management of advanced testicular teratoma |
| Q43974233 | The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. |
| Q35024008 | The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing |
| Q36142060 | The role of genetic breast cancer susceptibility variants as prognostic factors |
| Q21562160 | The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine |
| Q46364450 | The search for low-penetrance breast cancer genes. |
| Q31106285 | The study of nevi in British twins: Study design and description of the data set |
| Q34151528 | Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies |
| Q114677146 | Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction |
| Q89961489 | Transcriptome-wide association study of breast cancer risk by estrogen-receptor status |
| Q56625730 | Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles |
| Q51974477 | Two ATM variants and breast cancer risk. |
| Q43051933 | Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. |
| Q34354479 | Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene |
| Q92994868 | Two truncating variants in FANCC and breast cancer risk |
| Q115601277 | Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry |
| Q50084544 | Use of deep whole genome sequencing data to identify structure risk variants in breast cancer susceptibility genes. |
| Q38721663 | Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries |
| Q89637984 | Using human genetics to understand the disease impacts of testosterone in men and women |
| Q38814549 | VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis |
| Q52725335 | Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. |
| Q36503573 | Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG) |
| Q33904964 | Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility |
| Q34129771 | Variants in DNA double-strand break repair genes and breast cancer susceptibility |
| Q56342454 | Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility |
| Q29417028 | Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer |
| Q77857319 | Variation in BRCA1 cancer risks by mutation position |
| Q34044197 | Variation in cancer risks, by mutation position, in BRCA2 mutation carriers |
| Q71955901 | Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene |
| Q79255939 | Where are the prostate cancer genes?—A summary of eight genome wide searches |
| Q33989477 | Younger age-at-diagnosis for familial malignant testicular germ cell tumor |
| Q69922703 | [The genetics of medullary cancer of the thyroid] |
| Q42695202 | pedigreejs: a web-based graphical pedigree editor |
| Q37414133 | rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk |
| Douglas Easton | wikipedia |
Search more.